Asthma

Nektar Therapeutics presented Phase 2b REZOLVE-AD data at ACAAI 2025, highlighting rezpegaldesleukin’s potential in atopic dermatitis and comorbid asthma. The study showed statistically significant reductions in Asthma Control Questionnaire (ACQ-5) scores in patients with both conditions. Notably, patients with poorly controlled asthma experienced even greater improvements. These findings suggest that rezpegaldesleukin, an IL-2 pathway agonist, may offer benefits beyond skin symptoms by promoting regulatory T-cell activity. Phase 3 trials are planned.

The EVEREST Phase 4 trial presented at the 2025 EAACI conference demonstrated that Dupixent outperformed Xolair in treating chronic rhinosinusitis with nasal polyps and asthma. The study showed superior results for Dupixent across all endpoints for both conditions, including nasal polyp size reduction, improved smell, and enhanced lung function. This head-to-head comparison represents a significant milestone in respiratory disease treatment.

Upstream Bio announced promising data on verekitug, a lead candidate targeting the TSLP receptor, presented at the EAACI Congress. Modeling data suggests enhanced potency compared to tezepelumab, potentially offering a differentiated profile across inflammatory diseases like asthma, COPD, and CRSwNP. Phase 2 trials for CRSwNP are expected in Q3 2025, followed by severe asthma data in 2026’s first half.